This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
KLOW
Our depth — beyond the mirror
Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.
▸ Editor's verdict WATCH-LIST MEDIUM
"For this user specifically — KLOW is a multi-component stack where the GLOW subset (GHK-Cu + BPC-157 + TB-500) already overlaps directly with the planned cubital tunnel cycle, and KPV may add value if perioral dermatitis persists despite clotrimazole + behavioral fixes. The full KLOW (with LL-37) is not load-bearing for this user's current targets — LL-37 is the wildcard with the thinnest evidence base, the hardest sourcing, and the only component with cytotoxicity-at-high-concentration concerns. WATCH-LIST means: keep the 3-peptide GLOW subset on the active shortlist for the cubital tunnel + skin protocol (already documented in stacks/cubital-tunnel-cycle.md and stacks/klow-glow-stack.md), but do not run the full 5-peptide KLOW unless skin/gut symptoms escalate to a degree that justifies the LL-37 sourcing/cost overhead. Confidence is MEDIUM because (a) zero clinical trials exist on this specific blend, (b) each component has its own evidence-base limitations (single-lab dominance for BPC-157, sparse human data for KPV/LL-37, gray-market sourcing variability across all 5), and (c) the synergy claim is mechanism-plausible but not RCT-validated. Would upgrade to OPTIONAL-ADD if (a) this user's perioral dermatitis or gut symptoms escalate AND clotrimazole/behavioral fixes fail, (b) the cubital tunnel cycle plateaus on BPC-157 + TB-500 alone and adding GHK-Cu + KPV produces incremental gain. Would downgrade to SKIP-FOR-NOW if behavioral measures resolve cubital tunnel + skin issues without peptide intervention."
▸ Drug interactions deep dive
Compatible with
- All of the user's V stack/V5 base stack — no documented interactions
- Cerebrolysin cycles — different mechanism layers (CNS vs peripheral)
- Cognitive stim layer (modafinil, bromantane) — no known interaction
- TRT/HRT — no HPG-axis effect from any KLOW component
Avoid combining with
- High-dose corticosteroids — anti-trophic conflict
- Active chemotherapy — angiogenesis-stimulation concern
- High-dose chronic NSAIDs — may blunt healing-phase inflammatory signaling
- Ketamine within 24 hr — theoretical NMDA-trophic conflict (same flag as Cerebrolysin)
- VEGF inhibitors (bevacizumab, ranibizumab) — mechanism-opposing
▸ Pharmacogenomics
Minimal data. KLOW components act via signaling cascades (VEGFR2, NOS, GH-R, MC1R/MC5R, NF-κB, copper redox) rather than single-enzyme metabolism. No known polymorphism that meaningfully alters KLOW response has been identified. When the user's 23andMe results land (~June 2026), no specific KLOW-relevant variants to look for. Indirect: reduced eNOS function variants (rare) might blunt BPC-157's angiogenic effect; copper-related variants (e.g., ATP7B) are theoretical concerns for GHK-Cu but no clinical data.
▸ Sourcing deep dive
KLOW requires either (a) a pre-blended vendor product or (b) sourcing 4-5 separate peptides. Both paths have research-chem risk.
Pre-blended KLOW vendors
| Path | Vendor | Cost | Reliability | Notes |
|---|---|---|---|---|
| Pre-blended 80 mg vial (4-peptide canonical) | Vital Body Therapeutics, Limitless Life, Pep-Pedia partner vendors | $200-400 per vial | Medium | Convenient single injection, fixed 5:1:1:1 ratio, less dosing flexibility. COA per blend, not per component. |
| Compounding pharmacy | Effectively prohibited (FDA Category 2 for BPC-157, March 2024) | N/A | N/A | Not a viable path in US. |
Component-by-component sourcing (preferred for users in this archetype)
| Component | Vendor | Cost per cycle | Reliability |
|---|---|---|---|
| KPV | Peptide Sciences, Limitless Life, Cosmic Peptides | $80-120 | Medium |
| LL-37 | Limited gray-market vendors | $100-200 | Low-Medium (sourcing harder) |
| GHK-Cu | Peptide Sciences, Limitless Life | $80-150 | Medium-High |
| BPC-157 | Limitless Life, Pure Peptides USA, Peptide Sciences, Umbrella Labs | $40-80 | Medium-High |
| TB-500 | Same vendors as BPC-157 | $80-150 | Medium-High |
Cost summary
- Full KLOW (5-peptide) per cycle: ~$380-700
- Pep-pedia 4-peptide KLOW per cycle: ~$280-500
- GLOW (3-peptide subset) per cycle: ~$200-380
Verification protocol
- Request batch-specific COA per peptide (HPLC purity ≥98%, mass spec MW confirmation, endotoxin <0.5 EU/mg).
- Reconstitute with bacteriostatic water (not plain sterile water).
- Visual inspection: clear, no particulates, no cloudiness.
- Refrigerate; use within 30 days post-reconstitution.
▸ Biomarkers to track (deep)
Baseline (before any cycle)
- hsCRP — systemic inflammation; expect modest reduction on full KLOW
- IL-6 — cytokine; less standard but informative
- Skin photo log — consistent lighting, all anatomic regions of concern (face, groin, etc.)
- Hair density photo log — if hair use case is in play (the user: not currently)
- Joint pain self-report — 1-10 scale, AM and PM, both elbows for users in this archetype
- Cubital tunnel objective metrics — Tinel's sign at medial epicondyle, 2-point discrimination at ring/small finger, grip + pinch strength dynamometer
- Sleep quality — Oura ring data, baseline 4-week average
- Gut symptom diary — reflux, bloat, bowel pattern (KPV + BPC-157 modulate these)
During cycle (week 2, 4, 6)
- Daily injection-site observation (any redness, induration, lumps)
- Weekly subjective rating of target outcome (skin, hair, joint pain, nerve symptoms)
- hsCRP at week 4 (modest reduction expected on full KLOW)
- Photo log update at end of cycle
Post-cycle (4 weeks after last dose)
- Re-photograph skin/hair
- Repeat hsCRP
- Re-test cubital tunnel objective metrics
- Decision: cycle again, drop to GLOW maintenance, or stop
▸ Controversies / open debates Live debate
Acronym ambiguity. "KLOW" is community-developed; pep-pedia canonical is 4-peptide (no LL-37); peptide forums often include LL-37 as the "L." No formal definition exists. Always specify which variant when discussing.
No clinical trials on the blend. Each component has its own (limited) evidence base; the blend itself has zero controlled trials. Synergy claims are mechanism-plausible but not RCT-validated.
Blend vs separate vials. Pre-blended saves friction but loses dosing flexibility and adds QC risk. For specific targets (e.g., nerve compression), separate vials with target-specific dosing are preferred.
LL-37 cytotoxicity at high doses. LL-37 punches holes in cell membranes (that's how it kills bacteria), but the same mechanism can damage host cells if dosing is wrong. Concentration-dependent. Forum dosing (100-200 mcg SC 2-3×/week) is below the cytotoxic threshold per available data, but the safety margin is thinner than for other peptides.
GHK-Cu sourcing variability. Counterfeit GHK-Cu (no copper bound, or wrong stoichiometry) is common. The copper component is essential to the mechanism — verify COA shows copper content, not just GHK peptide.
Single-lab dominance for BPC-157. >80% of BPC-157 evidence is from Sikiric's group at University of Zagreb. Open 2024-2025 academic dispute about confirmation bias and lack of independent replication. See bpc-157.md for full discussion.
FDA 2024 prohibition. BPC-157 + TB-500 are FDA Category 2 on the interim 503A bulks list (March 2024 — compounding effectively prohibited). Research-chem peptide market continues. Legal gray zone.
▸ Verdict change log
- 2026-05-06 — Initial verdict: WATCH-LIST for users in this archetype. Full 5-peptide KLOW is not justified by current targets — cubital tunnel is BPC-157 + TB-500 territory (already covered by GLOW subset planned for stacks/cubital-tunnel-cycle.md), skin issues are first-line treatment territory (clotrimazole + behavioral), and there's no chronic infection indication that justifies the LL-37 differentiator. KPV worth single-component test if perioral dermatitis persists; otherwise hold full KLOW as a "decision tree endpoint" rather than a default. Confidence MEDIUM because the individual components have varying evidence quality (BPC-157 single-lab dominance, LL-37 sparse data, GHK-Cu/KPV/TB-500 reasonable mechanism + animal data) and the blend has zero clinical trials. Would upgrade to OPTIONAL-ADD if escalation triggers met (see verdict-rationale).
▸ Open questions / gaps Open
Blend vs separate-vial efficacy. No published comparison. Mechanism suggests separate vials with target-specific dosing should outperform a fixed-ratio blend for focal targets, but no data.
KPV oral vs SC for skin indications. Oral KPV (0.5-2 mg capsule) is convenient and likely sufficient for systemic anti-inflammatory action; SC may be needed for direct skin/gut contact. Forum reports favor SC for IBD, oral for general inflammation. Sparse human data either way.
LL-37 dosing safety margin. Forum dosing is below cytotoxic threshold per available data, but the threshold is concentration-dependent and varies by tissue. No human dose-response curve published.
Per-component sourcing confidence aggregated risk. With 5 peptides, the probability of at least one bad vial in a cycle is non-trivial. No published estimate.
Long-term safety (>8 weeks continuous human use). Unknown for any component. Repeated cycles with wash periods is the standard pattern; continuous open-ended use is not advised.
Pep-pedia poll data interpretation. N=386 currently using, primary goal Recovery/Healing (50%), Anti-aging (20%), General wellness (22%). 39% "definitely yes" recommend, 32% "not sure," 24% "probably yes." Effectiveness rating skews "too early to tell" (49%) — the user base is largely early-cycle. One reported severe histamine reaction within 8 minutes of SC injection. Use poll data as directional, not validation.
▸ Cross-references
Component compound files
- kpv.md — anti-inflammatory tripeptide
- ll-37.md — cathelicidin antimicrobial peptide
- ghk-cu.md — copper tripeptide for collagen + skin/hair
- bpc-157.md — gut/joint/nerve regeneration peptide
- tb-500.md — Thymosin Beta-4 fragment
Related stacks
/home/ddb/projects/biohacking/research/stacks/klow-glow-stack.md— full stack-page write-up with week-by-week schedule (already exists, this file complements it)/home/ddb/projects/biohacking/research/stacks/cubital-tunnel-cycle.md— BPC-157 + TB-500 protocol for users in this archetype's actual nerve compression target- glow.md — 3-peptide subset (GHK-Cu + BPC-157 + TB-500), the regeneration core
Community references
/home/ddb/projects/biohacking/research/pep-pedia-mirror/api/peptides-all.json— pep-pedia canonical 4-peptide KLOW definition (5:1:1:1 ratio, 80 mg blend)/home/ddb/projects/biohacking/research/pep-pedia-mirror/api/polls/klow.json— pep-pedia user poll data (N=2,221 responses across question set)/home/ddb/projects/biohacking/research/pep-pedia-mirror/site/peptides/klow.html— pep-pedia rendered KLOW protocol page
Profile context
/home/ddb/projects/biohacking/research/_PROFILES/this-user.md— the user's specific archetype, current targets, preferences/home/ddb/projects/biohacking/research/_PROFILES/archetype-recovery-focused.md— recovery-focused archetype mapping
References
Vital Body Therapeutics — KLOW protocol article
vendor/practitioner write-up of 5-peptide variant
View SourceBPC-157 component file
full mechanism + evidence + sourcing for the angiogenesis/nerve lane
View SourcePep-pedia poll data — klow.json
N=2,221 user responses across usage/effectiveness/side-effects
View SourcePPInteractions6 compounds▸
| Peptide | Status | Note |
|---|---|---|
GLOW Protocol | Use Caution | KLOW already contains all GLOW components plus KPV - combining would result in double dosing of base peptides |
Ipamorelin | Unknown | No studies on combination - theoretical compatibility based on different mechanisms |
NAD+ | Unknown | No data on combining KLOW with NAD+ - both affect cellular processes through different pathways |
Anticoagulants | Use Caution | Components may affect wound healing and clotting - medical supervision required |
Growth Hormone | Avoid Combination | Multiple components affect GH pathways - risk of excessive stimulation |
Immunosuppressants | Use Caution | Components may interfere with immunosuppressive therapy - consult physician |
PP Community insights — click to load ▸
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.